Date: 06/26/2020
Category: Corporate Update
June 2020 Update
Over the past quarter, Ichnos has completed the steps required to form an independent
company, including the transition of colleagues in the United States and Switzerland to
Ichnos Sciences. Due to difficulties encountered in obtaining approval from the authorities
in India, Glenmark employees who were previously expected to transfer to Ichnos will
remain with Glenmark. These individuals will continue to do work for Ichnos on NCE for
the treatment of cancer through an agreement between the two companies.
To read more, download the full update PDF.
Recent updates
-
May 2023 Update
. Read more
- Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442. Read more
-
February 2023 Update . Read more
- Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting. Read more
-
November 2022 Update . Read more
View Career Opportunities
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
